Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytosorbents Cor
(NQ:
CTSO
)
1.010
UNCHANGED
Streaming Delayed Price
Updated: 11:10 AM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cytosorbents Cor
< Previous
1
2
3
4
5
Next >
Analyst Scoreboard: 5 Ratings For CytoSorbents
October 22, 2024
Via
Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts
October 22, 2024
Via
Benzinga
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
October 22, 2024
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
October 17, 2024
From
CytoSorbents
Via
GlobeNewswire
Recap: CytoSorbents Q4 Earnings
March 14, 2024
Via
Benzinga
A Preview Of CytoSorbents's Earnings
March 13, 2024
Via
Benzinga
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
October 01, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
August 27, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2024
From
CytoSorbents
Via
GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
August 13, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
August 13, 2024
CytoSorbents CFO Kathleen P. Bloch Retires
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
August 01, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 29, 2024
“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
July 17, 2024
From
CytoSorbents
Via
GlobeNewswire
Why CytoSorbents (CTSO) Stock Is Trading Higher
July 02, 2024
CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit facility with Avenue Capital Group.
Via
Benzinga
CytoSorbents Secures $20 Million Credit Facility
July 02, 2024
Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
June 24, 2024
Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
June 13, 2024
By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
June 05, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
June 04, 2024
From
CytoSorbents
Via
GlobeNewswire
CTSO Stock Earnings: CytoSorbents Meets EPS, Beats Revenue for Q1 2024
May 09, 2024
CTSO stock results show that CytoSorbents met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
CytoSorbents Reports First Quarter 2024 Results
May 09, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
May 02, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
April 26, 2024
From
CytoSorbents
Via
GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
April 17, 2024
From
CytoSorbents
Via
GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
March 14, 2024
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
From
CytoSorbents
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.